Published on 02/12/2025

QS for Single-Use: Records and Governance

In the evolving landscape of biologics and advanced therapy medicinal products (ATMP), single-use systems have emerged as a critical component enabling manufacturers to address the complexities of aseptic processing. This detailed tutorial provides a comprehensive guide on the governance and record-keeping aspects essential for the validation of these systems, aligning with regulatory expectations from major agencies such as the FDA, European Medicines Agency (EMA), and MHRA. Specifically, it delves into key considerations regarding viral clearance validation, the execution of spiking studies, and adherence to the aseptic controls as detailed in Annex 1 of the EU GMP guidelines.

Understanding the Landscape of Single-Use Systems

The implementation of closed systems and single-use technologies is revolutionizing the manufacture of biologics and ATMPs. Their advantages, such as reduced risk of cross-contamination and simplified cleaning processes, are paramount in aseptic processing environments. However, despite their benefits, regulatory compliance is critical. The design and validation of single-use systems must meet rigorous standards to ensure product quality, safety, and efficacy.

To successfully validate a single-use system, it is essential to perform a thorough assessment involving various components of Good Manufacturing Practice (GMP). This includes understanding the interaction between product, process, and system, which ultimately affects the identity, quality, and safety of the biologic product being manufactured.

Primary Components of Single-Use Systems

• Materials of Construction: Understanding the polymer properties and their interaction with products is essential in the validation. Selection of materials is governed by their ability to maintain sterility and withstand process conditions.
• Component Configuration: System design must ensure that all components are compatible, reducing the risk of leaks or contamination.
• Process Parameters: Define critical process parameters (CPPs) that impact product quality. Monitoring these during operations assures adherence to predetermined quality criteria.
• Cleaning and Sterilization: Although single-use systems minimize cleaning requirements, understanding how they can be chemically and thermally validated is crucial.

Documenting the Chain of Identity and Custody

The chain of identity and custody (COI/COC) is a mandatory practice in the manufacture of biologics, ensuring traceability from raw materials through to finished products. In the case of single-use systems, establishing robust documentation practices is critical to maintain regulatory compliance. All stages from procurement, usage, and waste disposal of single-use materials must be documented meticulously. This is particularly relevant for ensuring that each component can be traced back to its origin and can be linked to specific batches of product.

Steps to Establish a Robust COI/COC Framework

• Vendor Qualification: Ensure suppliers of single-use components adhere to stringent quality control procedures and can provide necessary documentation.
• Component Acceptance Testing: Implement sampling and testing of components on receipt to verify their compliance with specified regulatory standards.
• Tracking and Traceability: Utilize a robust computerized tracking system that allows for real-time monitoring of the use of single-use materials, linked to specific production lots.
• Documentation Controls: Develop SOPs detailing record-keeping practices for all single-use materials, ensuring documents are readily available for inspections.

Viral Clearance Validation: Ensuring Safety in Manufacturing

Viral clearance validation is crucial for ensuring that any viral contaminants are effectively removed or inactivated during the processing of biologics. This assessment is vital not only for patient safety but is also a requirement of regulatory frameworks such as ICH Q5A(R2). Proper validation assures that the manufacturing process can successfully remove viral particles and meet acceptable safety standards.

Implementing Viral Clearance Studies

To perform viral clearance validation, a structured approach through spiking studies and subsequent analysis is indispensable. The following outlines a step-by-step methodology for executing these studies:

Step 1: Study Design

Define the scope and objectives of the viral clearance study. Determine the viral models to be used based on risk assessment and review of the viral characteristics.

Step 2: Selection of Viral Loads

Select appropriate viral loads to challenge the system. It is essential these loads reflect worst-case scenarios to demonstrate the effectiveness of the clearance for potential contaminants.

Step 3: Conducting Spiking Studies

• Preparation: Pre-treat viral models using established methodologies to ensure their integrity.
• Application: Spike the viral suspensions into the product matrix and perform the necessary processing steps through the single-use system.
• Sampling: At various points in the process, collect samples to assess viral levels post-processing.

Step 4: Analytical Testing

Analyzing the samples using validated assays to quantify viral titers before and after processing allows for determination of the process’s viral clearance efficiency. This data should then be compiled into a comprehensive report detailing the methodology, findings, and conclusion for regulatory submission.

Critical Quality Attributes and their Relevance

In the context of single-use systems, it is crucial to identify and validate Potency and Identity Critical Quality Attributes (CQAs). This ensures lot-to-lot consistency and compliance with predefined specifications. Emphasized in both FDA guidance and EMA regulations, understanding CQAs helps in characterizing your product’s identity and performance throughout its life cycle.

Steps for Defining and Validating CQAs

• Identify CQAs: Collaborate with cross-functional teams to determine attributes critical to product performance based on product nature, processing techniques, and intended use.
• Implementation of Control Measures: Develop control strategies to monitor CQAs through the manufacturing process, ensuring they remain within specified limits.
• Validation of Analytical Methods: Employ robust analytical methods validated as per ICH Q2(R1) guidelines to evaluate CQAs consistently.

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) for ATMP

Establishing a robust PPQ and CPV framework tailored for ATMPs is critical for ongoing assurance of product quality. The FDA emphasizes that process validation should encompass prospective, concurrent, and retrospective validation methodologies to ensure holistic coverage of the manufacturing process.

Steps for Effective PPQ and CPV Tailoring

• Defining the Process: Document and validate all steps in the manufacturing process, ensuring that each is in compliance with the established protocols.
• Creating a Validation Master Plan: A comprehensive plan that outlines all aspects of the validation strategy should be developed. This includes raw material qualification, in-process controls, and final product testing.
• Collecting Data for CPV: Implement a system for collecting and analyzing real-time data during manufacturing to identify trends and deviations, normalizing quality assurance.
• Regular Review: Schedule periodic reviews of the validation process and control measures to ensure they align with current regulatory expectations and scientific advancements.

Conclusion: Ensuring Compliance in a Regulatory Landscape

In summary, the validation of single-use systems in pharmaceutical manufacturing revolves around rigorous adherence to established regulatory frameworks while ensuring that the systems employed meet the standards for safety, efficacy, and quality. Proper documentation, governance, and rigorous testing protocols are critical for minimizing risk as well as ensuring regulatory compliance. By understanding the nuances of aseptic processing, viral clearance validation, and the regulatory expectations that pertain to closed systems, professionals in the field can enhance their practices and safeguard public health.

Compliance is not just a regulatory necessity; it is an ethical commitment to ensuring that all biologics and ATMPs delivered are safe for public use. Therefore, every stakeholder must prioritize the incorporation of these validation principles into their operations.